Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: CNBC
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 40.520
Low
42.00
Averages
54.67
High
70.00
Current: 40.520
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Etavopivat Trial Achieves Success
- Trial Success: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that etavopivat significantly reduced vaso-occlusive crises and improved hemoglobin response in 385 patients aged 12 and older over 52 weeks, achieving both co-primary endpoints and confirming the drug's efficacy.
- Safety Profile: The therapy exhibited a safety profile consistent with prior studies, indicating good tolerability, which enhances its potential for clinical application and may offer patients a safer treatment option for sickle cell disease.
- Regulatory Submission Plans: Novo Nordisk intends to submit a regulatory application for etavopivat in H2 2026, marking a critical step toward market entry, and if approved, it could provide new treatment options for sickle cell disease patients.
- Future Results Presentation: The company plans to present detailed trial results at an upcoming medical event, which could further drive interest and research into the drug, potentially attracting more investors and healthcare professionals to its innovative treatment approach.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Novo Nordisk's Etavopivat Phase 3 Trial Achieves Key Success
- Trial Results: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that Etavopivat met both co-primary endpoints in 385 patients with sickle cell disease, significantly outperforming placebo.
- Efficacy Highlights: Patients treated with Etavopivat experienced a 27% reduction in the annualized rate of vaso-occlusive crises (VOCs), with 48.7% achieving a hemoglobin increase of over 1g/dL after 24 weeks, compared to just 7.2% in the placebo group.
- Safety Profile: The trial indicated that Etavopivat was well tolerated, with a safety profile consistent with previous studies, suggesting a favorable risk-benefit ratio for future use.
- Future Prospects: Novo Nordisk plans to submit for regulatory approval of Etavopivat in the second half of 2026, with the FDA granting it Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting its significant market potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Novo Nordisk's Etavopivat Trial Achieves Success
- Trial Success: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that etavopivat significantly reduced vaso-occlusive crises and improved hemoglobin response in 385 patients aged 12 and older over 52 weeks, achieving both co-primary endpoints and confirming the drug's efficacy.
- Safety Profile: The therapy exhibited a safety profile consistent with prior studies, indicating good tolerability, which enhances its potential for clinical application and may offer patients a safer treatment option for sickle cell disease.
- Regulatory Submission Plans: Novo Nordisk intends to submit a regulatory application for etavopivat in H2 2026, marking a critical step toward market entry, and if approved, it could provide new treatment options for sickle cell disease patients.
- Future Results Presentation: The company plans to present detailed trial results at an upcoming medical event, which could further drive interest and research into the drug, potentially attracting more investors and healthcare professionals to its innovative treatment approach.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Novo Nordisk's Etavopivat Phase 3 Trial Achieves Key Success
- Trial Results: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that Etavopivat met both co-primary endpoints in 385 patients with sickle cell disease, significantly outperforming placebo.
- Efficacy Highlights: Patients treated with Etavopivat experienced a 27% reduction in the annualized rate of vaso-occlusive crises (VOCs), with 48.7% achieving a hemoglobin increase of over 1g/dL after 24 weeks, compared to just 7.2% in the placebo group.
- Safety Profile: The trial indicated that Etavopivat was well tolerated, with a safety profile consistent with previous studies, suggesting a favorable risk-benefit ratio for future use.
- Future Prospects: Novo Nordisk plans to submit for regulatory approval of Etavopivat in the second half of 2026, with the FDA granting it Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting its significant market potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
